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Chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases and the fourth
cause of death in the world. Its advanced forms (severe — in case of FEV1 indicator below 50% of the norm
and very severe — below 30%) usually lead to respiratory disability and premature death. The prognoses of
those suffering from severe forms of COPD are no different from patients with lung cancer. The course of the
disease is highly influenced by its exacerbation and co-morbidities, such as cardiovascular diseases, diabetes,
lung cancer and peptic ulcer.
Treatment aims at stopping the progress of disease, preventing its exacerbation and relieving tiresome
symptoms, mainly dyspnoea, chronic cough and decreasing tolerance of effort.
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The clinical picture of advanced COPD
The number of patients affected by chronic ob-
structive pulmonary disease (COPD) in Poland is es-
timated at 2 million with a considerable percentage
suffering from severe (15%) or very severe (3%) dis-
ease. This means that the number of patients with
advanced COPD in our country may be as high as
400,000.
Chronic obstructive pulmonary disease is defined
as an illness with a progressive, poorly reversible
airflow limitation in the respiratory tract resulting
from inflammation triggered by noxious fumes and
gases. Extrapulmonary consequences of COPD and
comorbidities may adversely affect the course of
the disease [2].
Spirometric manifestations of bronchial obstruc-
tion in the course of COPD include reduced FEV1/
FVC below 70% predicted and the lack of revers-
ibility of bronchoconstriction following adminis-
tration of a bronchodilator, while progression of
the disease is manifested by an increasing FEV1.
Severe and very severe COPD is defined as FEV1
reduction below 50% and 30% predicted, respec-
tively [2].
The clinical picture of advanced COPD generally
consists of:
— severe respiratory manifestations;
— systemic and extrapulmonary manifestations;
— comorbidities;
— recurrent exacerbations;
— mental status changes.
An additional element that is less frequently in-
cluded in the descriptions of advanced COPD is the
increasing family, professional and social isolation
of patients and the need to provide support to the
patient's family and those caring for the patient.
Respiratory manifestations
Most patients with advanced COPD suffer from
dyspnoea often accompanied by severe cough and
sputum production (especially in the morning). This
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is for the most part a result of chronic inflammation
of the bronchial mucosa and the chest congestion
caused by destruction of the respiratory epitheli-
um. Replacement of respiratory by squamous epi-
thelium (foci of metaplasia), reduced or absent cili-
ary response, impaired secretory function of the
mucous glands of the respiratory tract and the im-
paired function of macrophages are just some of
the mechanisms that lead to reduced airflow in the
bronchi due to chest congestion. The bronchospasm
results, as already mentioned, from chronic inflam-
mation leading to bronchial wall remodelling but
also from destruction of the parenchymal structure
caused by emphysema. This leads to the formation
of an air trap and eventually to hyperinflation man-
ifested by increased total lung capacity (TLC) and
residual volume (RV). The development of emphy-
sema also damages the natural “scaffolding” of the
pulmonary parenchyma that allows to preserve an
appropriately wide bronchial lumen, especially dur-
ing expiration. The loss of elastic elements of the
parenchyma leads to bronchial “collapse” during
the passive phase of expiration and forces the pa-
tient to use the auxiliary respiratory muscles. All
this is manifested by increased pulmonary resistance,
reduced closing volume (CV) and reduced maximal
expiratory flows (MEF) in the so-called small calibre
bronchi test (MEF75, MEF50 and MEF25) below 60%
predicted. These changes are also responsible for
the considerable reduction in exercise tolerance
among patients with advanced COPD.
Systemic and extrapulmonary manifesta-
tions
Chronic obstructive pulmonary disease is accom-
panied by systemic inflammation, as evidenced by
increased serum levels of C-reactive protein (CRP)
and increased production of tumour necrosis factor
alpha (TNFa) and other proinflammatory cytokines.
Isolated studies have shown the presence of anti-
bodies to elastin in the serum, which might demon-
strate that COPD is a chronic autoimmune disease
[3]. This hypothesis has not, however, been unequiv-
ocally confirmed.
Advanced COPD is often complicated by os-
teoporosis [4]. The reason for this phenomenon re-
mains unclear, although it is hypothesised that
proinflammatory cytokines that trigger processes
accelerating bone degradation may play an impor-
tant role in the pathomechanism of osteoporosis in
COPD patients.
An important abnormality affecting the course
of COPD is muscle weakness with the associated
reduction in lean body mass. Many studies have
demonstrated a reduced mass of large muscles, such
as the femoral muscle [5]. Muscle weakness is one
of the factors leading to wasting syndrome [6, 7].
In addition, it is believed that changes in the levels
of TNF-  and leptin observed during exacerbations
of COPD may be related to poorer nutritional status
and muscle weakness [8].
Comorbidities
The frequent coexistence of COPD with other
diseases, such as cardiovascular disease, diabetes
mellitus, lung cancer and peptic ulcer disease, is
increasingly drawing attention [9]. The factor that
may significantly affect the occurrence of these con-
ditions is smoking. Smoking results in local changes
secondary to noxious effects of the toxic compounds
present in cigarette smoke, on the one hand, lead-
ing to increased secretion of proinflammatory cy-
tokines, such as TNF-a, on the other hand [10].
Repeated exacerbations
Most patients with advanced COPD demon-
strate a constant progression of the disease that is
interrupted by periodic exacerbations. Exacerba-
tions may be:
— mild — characterised by an increased demand
for medications although the patient can cope
without additional medical assistance
— moderate — where the patient requires medical
assistance in the outpatient setting in addition
to the increased demand for medications;
— severe — generally defined as a sudden worsen-
ing of signs and symptoms that requires hospi-
talisation [11].
Patients with severe COPD suffer from an aver-
age of 2–3 exacerbations annually [12, 13], although
it seems that exacerbations mainly affect patients
with increased bronchial secretion [14]. Frequent
exacerbations, especially those requiring hospitali-
sation, adversely affect the prognosis and are asso-
ciated with increased mortality [15]. The most com-
mon causes of exacerbations (50–70% of the cases)
include recurrent respiratory infections, cardiovas-
cular events, acute exacerbation of congestive heart
failure, exacerbation of the signs and symptoms of
pulmonary heart disease [16]. Exacerbations may
also be caused by pulmonary embolism. A system-
atic review of five papers, four of which were pub-
lished between 2000 and 2007 and one in 1992,
demonstrated that pulmonary embolism was a com-
mon cause of COPD exacerbation (being observed
in nearly 20% of the patients) [17]. It should be
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remembered that increased exposure to environ-
mental factors or incorrect intake of medications
may also precipitate exacerbations [18].
Mental status changes
The permanent reduction of exercise capacity and
the persistent respiratory and systemic symptoms
considerably decrease the quality of life [19, 20]. It
seems that during exacerbations the quality of life
additionally deteriorates, returning to baseline with-
in at least two weeks following resolution of the
incident [21]. Frequent exacerbations also perma-
nently reduce the quality of life [22]. In most pa-
tients the severity of the disease leads to the feeling
of social isolation [12]. The patient's unfavourable
position often results in depression and anxiety,
which in turn augment the perception of symptoms
and worsen the quality of life, leading to a vicious
circle. It has been demonstrated that anxiety and
depression most commonly occur together [23], and
the risk of depression in patients with severe COPD
is 2.5-fold higher than that in healthy individuals.
The American College of Chest Physicians (ACCP)
points to the coexistence of anxiety and depression
with such factors, as physical disability, comorbidi-
ties, home oxygen therapy, severe dyspnoea and
reduced quality of life and with social factors, such
as low social status and lonesomeness [24, 25]. Both
anxiety and depression are more prevalent in wom-
en [23].
Prognosis
Prognosis in severe COPD is poor and compara-
ble to that in advanced lung cancer. Five-year sur-
vival ranges from 50% to 26%, depending on the
author [26, 27]. The prognosis is even worse in
patients with hypercapnic respiratory failure. For
example, over 29 months of follow-up the mortal-
ity rate in this group of patients was 32% [27]. In
the group requiring mechanical ventilation for
acute respiratory failure in the course of COPD
exacerbation the mortality rate was 24% during
hospitalisation and 75% over the next five years
with a higher risk of death in the elderly and pa-
tients with a history of exacerbations requiring
mechanical ventilation [28]. The mortality rate in
patients over 65 years of age requiring hospitali-
sation for COPD exacerbation was slightly more
than 7% during hospitalisation and 54% over the
next five years. The factors that increased mortali-
ty included reduced FEV1 values, increased CO2 re-
tention on admission, ischaemic heart disease, pre-
vious hospitalisations for COPD exacerbation and
smoking [29].
Other factors that affect the prognosis include
the severity of dyspnoea measured on the Medical
Research Council (MRS) scale, body mass index
(BMI), severity of obstruction as measured by FEV1
and exercise capacity measured in the 6-minute
walk test. These factors form the basis for the
BODE index (Body mass index, Obstruction, Dysp-
noea, Exercise capacity) [30], which assesses the
risk of exacerbations requiring hospitalisation or
leading to death [31]. It should be emphasised
that the mortality rate in COPD patients depends
on the number of exacerbations requiring hospi-
talisation [32].
Inflammation in the respiratory tract is an im-
portant element affecting the course of COPD [33],
and the increased sputum neutrophil count is as-
sociated with FEV1 reduction [34]. In addition, ele-
vated serum CRP (an inflammation marker) con-
siderably increases the risk of myocardial infarc-
tion [35]. It should, however, be noted that a re-
cent study suggests a limited role of CRP in the
assessment of prognosis in patients with moder-
ate to severe COPD [36].
Treatment
The principal aims of treatment in COPD are to
stop progression of the disease and counteract func-
tional deterioration of the respiratory system as
measured by FEV1. Additional goals in advanced
COPD are to relieve troublesome symptoms and pre-
vent exacerbations.
Bronchodilators
Medications used on the as-needed basis include
short-acting b2-agonists, ipratropium or combina-
tions thereof, such as fixed combinations of fenot-
erol and ipratropium. Although bronchodilators act
peripherally, it is believed that their long-term use
is more beneficial than periodic use [2].
Prolonged-action formulations, such as long-
acting b2-agonists, long-acting anticholinergic
agents and prolonged-release theophylline formu-
lations, are recommended in long-term treatment.
Results of the UPLIFT study have recently been pub-
lished. The study assessed the role of tiotropium
for the treatment of COPD [37]. It was demon-
strated that tiotropium improved pulmonary ven-
tilation (although it did not prevent the FEV1 de-
crease) and reduced the number of exacerbations
and cardiovascular mortality. It should be empha-
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sised that the effect persists during treatment and
tiotropium has a good safety profile and may be
used long-term [37]. In the majority of patients
with advanced COPD combination treatment with
two or three bronchodilators is used. This is well
justified, as such a combination additionally im-
proves pulmonary function and the patients’ health
[2]. This relationship has been confirmed by a re-
cently published randomised study demonstrating
that formoterol and tiotropium monotherapy for
24 weeks was less effective than the combination
product [38].
Inhaled glucocorticosteroids
In patients with advanced COPD suffering from
frequent exacerbations moderate-dose inhaled glu-
cocorticosteroids may be considered [2]. The use
of fixed combinations containing a glucocorticos-
teroid and a long-acting b2-agonist in one contain-
er seems more effective than using the two agents
as two separate formulations [39, 40]. The recent-
ly published randomised study to assess the anti-
inflammatory efficacy of salmeterol/fluticasone,
tiotropium/fluticasone and tiotropium demonstrat-
ed that the use of formulations containing flutica-
sone is associated with a significant reduction in
the concentrations of interleukin 8 (IL-8) and ma-
trix metalloproteinase 9 (MMP-9) at 3 months of
treatment [41]. This effect may be associated with
the improvement of COPD in patients with fre-
quent exacerbations. On the other hand it should
be emphasised that using the above drugs did not
affect neutrophil or eosinophil counts in the spu-
tum or CRP and pulmonary function parameters
[41]. It should, however, be taken into account
that the use of inhaled glucocorticosteroids does
not reduce mortality but does increase the risk of
pneumonia [42]. Systemic glucocorticosteroids are
recommended in exacerbations of COPD, while
there is no evidence to support the efficacy of long-
term treatment with these agents, especially in view
of the fact that adverse reactions, including ste-
roid myopathy, may significantly worsen the course
of the disease [43].
Home oxygen therapy
The principal aim of home oxygen therapy is to
increase pO2 above 60 mmHg (which roughly corre-
sponds to oxygen saturation values exceeding 90%)
with the view to ensuring appropriate tissue oxy-
genation. Eligibility for home oxygen therapy is
therefore determined on the basis of arterial blood
gas analysis values: pO2 < 55 mm Hg, SaO2 < 90%
or pO2 < 60 mm Hg with coexisting pulmonary
hypertension, polycythaemia (haematocrit > 55%),
radiological signs of pulmonary heart disease and/
/or signs of right ventricular hypertrophy.
Non-invasive ventilation
The benefits of non-invasive ventilation (NIV) in
exacerbations of COPD are well documented [44].
In many patients with exacerbations accompanied
by respiratory failure NIV offers the possibility to
avoid the use of a ventilator [45, 46]. Recent studies
have shown that in patients with severe COPD com-
bination use of NIV and oxygen therapy is more
effective than oxygen therapy alone in preventing
the exertional oxygen saturation drop. Unfortunate-
ly, this benefit is largely diminished by the inconve-
nience resulting from the need of appropriate equip-
ment [47]. NIV is also an alternative to mechanical
ventilation in terminal patients and allows to re-
duce the “breathing exertion” and the subjective
feeling of dyspnoea [48, 49]. The benefit of NIV in
palliative care in patients with advanced COPD have
not been established.
Surgical methods
Surgical methods are available only for few well-
selected patients (bullectomy, lung volume reduc-
ing surgery, lung transplantation) or as part of clin-
ical studies (intrabronchial stents) [50]. Lung vol-
ume reducing surgery is aimed to improve ventila-
tion and, as a consequence, spirometry values. Pre-
vious reports suggested the possibility of increas-
ing exercise capacity, reducing dyspnoea and im-
proving the quality of life. Long-term results, how-
ever, vary greatly and depend on the type of sur-
gery (unilateral versus bilateral) and the expertise of
the medical centre. Results of the National Emphy-
sema Treatment Trial suggest no advantage of lung
volume reducing surgery in improving survival of
patients with COPD and a slight advantage in the
group of patients with emphysema of the superior
pulmonary lobes and a low baseline exercise capac-
ity [51]. At the same time an increased mortality
and a lack of functional improvement in patients
with emphysema of the remaining pulmonary lobes
have been observed [51].
Bullectomy offers the greatest benefit to pa-
tients with single or multiple bullae located at least
the upper third of the lung with shifting and com-
pression of the healthy pulmonary parenchyma and
rapidly deteriorating dyspnoea [52]. Bullectomy
generally leads to a brief improvement of restric-
tive signs and symptoms and increases lung ca-
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pacity, exercise capacity and the quality of life,
and in some cases improves hypoxaemia, hyper-
capnia and dyspnoea. The beneficial effects of bul-
lectomy are maintained for at least 5 years in 33–
50% of the patients. The procedure, however, is
associated with a high perioperative mortality rate
of up to 22% [52].
The data regarding long-term outcomes of
more extensive procedures in the remaining por-
tion of the pulmonary parenchyma are inconclu-
sive.
According to the United Network for Organ Shar-
ing (UNOS), COPD is the most common indication
for lung transplantation [53]. Single-lung transplan-
tation increases FEV1 and FVC by about 50% pre-
dicted and 70% predicted, respectively, while dou-
ble-lung transplantation results in an increase in
FEV1 and FVC of up to 85% predicted and 92%
predicted, respectively [54]. Exercise capacity increas-
es proportionately in both methods. The quality of
life is improved considerably but only a few pa-
tients can resume full-time employment. The 1-year
and 5-year survival rates are 82% and 43%, respec-
tively [53]. The most common cause of death is
transplant rejection (up to 70%) [55].
Non-pharmacologic treatment
The American Thoracic Society (ATS) has recent-
ly published recommendations on palliative care for
patients with respiratory diseases [56]. In severe
chronic dyspnoea general and respiratory rehabili-
tation treatment including muscle exercises, respi-
ratory physiotherapy, patient education (including
dietary education) and psychological support are
recommended in addition to the pharmacologic
treatment typical of COPD. A systematic review of
randomised studies have shown that rehabilitation
allows to reduce dyspnoea and the feeling of ex-
haustion and to improve the patient's emotional
condition and disease control [57] in patients with
and without respiratory failure [58, 59]. Of note is
the fact that even patients with very advanced dis-
ease requiring chronic mechanical ventilation im-
prove their activity as a result of general training
and respiratory rehabilitation [60].
Opioids
The GOLD guidelines clearly point out that if
severe dyspnoea persists despite optimal treat-
ment administration of opioids should be consid-
ered [2]. It seems, however, that the use of opio-
ids in everyday practice is largely restricted by the
lack of knowledge regarding their proper use
among general practitioners and respiratory med-
icine specialists and by the belief that they are
associated with a high risk of life-threatening res-
piratory depression. Experience from the treatment
of dyspnoea in lung cancer patients seems to ques-
tion these concerns [61]. There is no consensus as
to the posology of morphine for dyspnoea in pa-
tients with advanced COPD. As is the case with
lung cancer patients, treatment should be started
from immediate-release formulations and regu-
larly administered doses of up to 2.5 mg. Careful
dose titration allows to establish individual re-
quirement for each patient. In cases of sudden
exacerbation of dyspnoea the “rescue” dose should
be 1/12 to 1/6 of the daily dose [62]. In patients
with insufficient response midazolam may be add-
ed [63].
Supportive treatment
In each form of COPD, including advanced COPD,
prevention of respiratory tract infection plays an
important role, especially in the elderly. Influenza
immunisations are recommended in all age groups
with additional pneumococcal immunisations in
patients over 65 years of age [2]. The justifiability of
chronic treatment with mucolytic agents, including
antioxidant formulations, such as N-acetylcysteine,
is still being debated. It seems that there is insuffi-
cient evidence to support the effectiveness of such
treatment [2, 64], although it seems justified to use
this drug class in exacerbations, especially in exac-
erbations accompanied by impaired bronchial se-
cretion.
Preventive or chronic use of antibiotics is not
recommended.
At any stage of the disease, however, including
very advanced disease, treatment of tobacco de-
pendence is recommended. There is convincing ev-
idence of improved pulmonary function and sur-
vival in patients who have ceased to smoke [65,
66]. An absolute prohibition to use home oxygen
therapy in chronic smokers is also an important
aspect.
It should be noted that in some patients with
advanced COPD an improved oxygenation of blood
may be achieved with almitrine, although this is
not considered a standard [67].
Summary
Advanced COPD carries a very poor prognosis
and patients experience severe respiratory and sys-
temic manifestations that may persist despite ap-
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propriate treatment. Everyday experience shows that
many patients are not effectively assisted. It there-
fore seems necessary to develop national recom-
mendations on palliative care for patients with ad-
vanced COPD.
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